To further investigate whether oncogenic KRAS activity could be influenced by stimulation of EGF or other HER-family related ligands, a panel of mutant KRAS NSCLC cells - H358 (KRASG12C; EGFRwt), H23 (KRASG12C; EGFRwt), A427 (KRASG12D; EGFRwt) and A549 (KRASG12S; EGFRwt amplification) - were serum starved overnight and then stimulated with epidermal growth factor (EGF) or neuregulin 1β (NRG1β) for ten minutes. This evidence concerns the gene KRAS and non-small cell lung carcinoma.